Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Raw Materials (2023 - 2024)

Harmony Biosciences Holdings (HRMY) has disclosed Raw Materials for 2 consecutive years, with $944000.0 as the latest value for Q4 2024.

  • Quarterly Raw Materials fell 10.94% to $944000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $944000.0 through Dec 2024, down 10.94% year-over-year, with the annual reading at $944000.0 for FY2024, 10.94% down from the prior year.
  • Raw Materials hit $944000.0 in Q4 2024 for Harmony Biosciences Holdings, down from $1.0 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $1.1 million in Q2 2024 to a low of $944000.0 in Q4 2024.